TNF Pharmaceuticals (TNFA) Stock Price, News & Analysis

Company Overview

TNF Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.

Key Stats

• Today's Range: $4.28 to $4.90
• 50-Day Range: $3.24 to $5.13
• 52-Week Range: $0.04 to $8.94
• Volume: 616,644 shs
• Average Volume: 32.22 million shs
• Market Capitalization: $8.00 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

TNF Pharmaceuticals Stock Analysis - MarketRank™

TNF Pharmaceuticals scored higher than 0% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.5 / 5
• Analyst Rating: Sell

Consensus Rating

TNF Pharmaceuticals has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

TNF Pharmaceuticals has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of TNF Pharmaceuticals is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of TNF Pharmaceuticals is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

TNF Pharmaceuticals has a P/B Ratio of 0.02. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for TNFA.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

TNF Pharmaceuticals does not currently pay a dividend.

Dividend Growth

TNF Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for TNF Pharmaceuticals this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, TNF Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.45% of the stock of TNF Pharmaceuticals is held by insiders.

Percentage Held by Institutions

9.64% of the stock of TNF Pharmaceuticals is held by institutions.

Company Calendar

• Last Earnings: 8/19/2025
• Today: 5/17/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TNFA
• Previous Symbol: NASDAQ:MYMD
• CIK: 1321834
• Web: tnfpharma.com
• Phone: (856) 848-8698
• Fax: 856-848-0269
• Employees: 6
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($231.00)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$23.36 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -69.21%
• Return on Assets: -33.98%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.93
• Quick Ratio: 0.93

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $286.76 per share
• Price / Book: 0.02

Miscellaneous

• Outstanding Shares: 1,847,000
• Free Float: 1,839,000
• Market Cap: $8.00 million
• Optionable: N/A
• Beta: 2.04